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Introduction 
For oral drug delivery of BCS class 2 and 4 drugs, it may be necessary to introduce innovative 
drug delivery systems to improve bioavailability. Micro fabricated devices have been 
proposed as promising oral drug delivery systems.
1 
Microcontainers consist of a walled 
reservoir extending from a flat base where size and shape easily can be controlled and also 
allowing for unidirectional drug release.
2
  
 
Aim   
The purpose of this study was to evaluate microcontainers in vitro and in vivo as an 
innovative oral drug delivery system for the poorly water-soluble drug, furosemide. 
 
Method 
SU-8 microcontainers (inner diameter of 223 µm) (Fig 1a) were filled with amorphous 
sodium salt of furosemide (ASSF), subsequently, the cavity was spray coated with Eudragit
® 
L100. The release of ASSF from the microcontainers was examined in biorelevant gastric and 
intestinal media and the intestinal permeability of ASSF dosed in microcontainers was 
evaluated using a Caco-2 cell culture model. Furthermore, the oral bioavailability of ASSF in 
microcontainers and in capsules coated with Eudragit® L100 were assessed. 
 
Results   
Drug release from microcontainers was prevented in the gastric medium, while an 
immediate release of ASSF was seen in the intestinal medium. The cell studies showed a fast 
permeability of ASSF with no significant differences between the microcontainers and bulk 
powder, Papp: 1.7±0.6·10
-5
 cm/s and 1.8±1.0·10
-5 
cm/s (mean±SD n=11), respectively (Fig 1b). 
The relative oral bioavailability of ASSF in microcontainers was found to be 220±43% 
(mean±SEM, n=6) when compared to drug-filled capsules coated with Eudragit
®
 which was 
reflected by a larger AUC for the ASSF in microcontainers (Fig 1c).   
  
Conclusion 
Microcontainers show considerable potential as a future oral drug delivery system. 
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Fig. 1 a) A microcontainer, inner 
diameter of 223 µm, b) intestinal 
permeability of ASSF filled into 
microcontainers in comparison with 
bulk powder, c) AUC0-1440 min for the 
plasma concentration of ASSF dosed 
in microcontainers and in Eudragit-
coated capsules after oral 
administration to rats.  
